Lymphoma is not lung cancer. They are two fundamentally different types of cancer that originate from different cells in the body. Lung cancer starts in the cells lining the airways or lung tissue, while lymphoma begins in white blood cells called lymphocytes, which are part of the immune system. The confusion often arises because lymphoma can sometimes appear in the lungs, creating overlapping symptoms and imaging findings that look similar on a CT scan.
Why These Two Cancers Are Different
Lung cancer and lymphoma differ at the cellular level. Primary lung cancers, including the two main types (non-small cell and small cell), grow from the epithelial cells that line the bronchial tubes and air sacs of the lungs. These cells are part of the respiratory system. Lymphoma, on the other hand, develops from lymphocytes, the immune cells that normally travel through your lymph nodes, spleen, and bloodstream to fight infection.
Because lymphocytes circulate throughout the body, lymphoma is generally considered a systemic disease. It can show up almost anywhere, including the chest. Lung cancer is an organ-specific cancer that may later spread to other sites. This distinction matters enormously for treatment: lymphoma typically responds to chemotherapy and targeted immune therapies, while early-stage lung cancer is more often treated with surgery to remove the tumor.
When Lymphoma Shows Up in the Lungs
Lymphoma can involve the lungs in two ways. The first, called primary pulmonary lymphoma, is rare. It accounts for less than 1% of all non-Hodgkin lymphomas and represents only 3 to 4% of lymphomas that develop outside the lymph nodes. The most common subtype is MALT lymphoma (a slow-growing cancer of immune tissue), which makes up 70 to 90% of primary pulmonary lymphoma cases.
The second and more common scenario is secondary pulmonary lymphoma, where a lymphoma that started elsewhere in the body spreads to the lungs. In a review of 180 patients with pulmonary lymphoma at a single medical center, nearly twice as many had secondary involvement (117 patients) compared to primary disease (63 patients). This happens because the lungs have extensive lymphatic tissue and blood flow, making them a frequent stop for circulating lymphoma cells.
Neither situation is lung cancer. Even when lymphoma forms a mass inside the lung that looks similar to a lung tumor on imaging, it remains lymphoma and is treated as such.
How Symptoms Overlap and Differ
Both conditions can cause a persistent cough, shortness of breath, and chest discomfort, which is one reason people wonder whether they might be the same disease. A mass in the lung creates similar mechanical problems regardless of what type of cancer it is.
Lymphoma, however, often comes with a distinct set of symptoms known as B-symptoms: unexplained fevers, drenching night sweats (the kind that soak through your sheets), and significant weight loss without trying. These systemic symptoms reflect the immune system’s response to the cancer and are less characteristic of lung cancer. Lung cancer is more likely to present with coughing up blood, persistent chest pain in one location, or recurrent lung infections.
Why Telling Them Apart Matters for Treatment
Getting the diagnosis right is critical because the treatment paths diverge sharply. Early-stage lung cancer is primarily treated with surgery to remove the tumor, sometimes followed by chemotherapy or radiation. The goal is to physically cut out the cancer before it spreads.
Lymphoma in the lungs is treated more like lymphoma anywhere else in the body. Chemotherapy and radiation are the two mainstream treatments. For B-cell lymphomas, a targeted antibody therapy called rituximab has significantly improved outcomes. Surgery generally does not offer additional survival benefits for pulmonary lymphoma because the disease tends to be multifocal (appearing in more than one spot within the lungs) and often requires systemic treatment to control. The treatment approach has shifted toward organ preservation rather than surgical removal.
Pulmonary MALT lymphoma in particular is slow-growing and carries a relatively favorable prognosis. Studies have found a five-year overall survival rate of about 67 to 69% for primary pulmonary lymphoma, with MALT and non-MALT subtypes showing similar outcomes. For comparison, lung cancer survival varies dramatically by stage, but the overall five-year survival rate for non-small cell lung cancer is considerably lower, particularly when diagnosed at advanced stages.
How Doctors Tell Them Apart
On a CT scan, pulmonary lymphoma can mimic lung cancer. It may appear as a mass or nodule with irregular margins, sometimes showing air bronchograms (visible air-filled bronchial tubes running through the mass), which are actually more common in lymphoma than in typical lung carcinomas. But imaging alone cannot make the diagnosis.
A tissue biopsy is essential. Pathologists examine the cells under a microscope and run specialized tests to determine whether the tumor cells are epithelial (pointing to lung cancer) or lymphoid (pointing to lymphoma). These tests look for specific markers on the cell surface. Lung cancer cells express markers related to lung tissue, while lymphoma cells express immune cell markers like CD20. In rare cases, small cell lung cancer can even mimic high-grade lymphoma under the microscope, making these detailed laboratory tests the only reliable way to distinguish the two.
If you or someone you know has a lung mass and the diagnosis is uncertain, the type of biopsy and the lab analysis performed on it will determine whether the condition is lung cancer, lymphoma, or something else entirely. The distinction shapes everything that follows, from the specialists involved in your care to the treatment plan and expected outcome.